Population-specific and transeethnic genome-wide analyses reveal distinct and shared genetic risks of coronary artery disease

Satoshi Koyama¹, Kaoru Ito^{1*}, Chikashi Terao², Masato Akiyama^{2,3}, Momoko Horikoshi⁴, Yukihide Momozawa⁵, Hiroshi Matsunaga^{1,6}, Hirotaka Ieki^{1,6}, Kouichi Ozaki^{1,7}, Yoshihiro Onouchi^{1,8}, Atsushi Takahashi⁹, Seitaro Nomura^{6,10}, Hiroyuki Morita⁶, Hiroshi Akazawa⁶, Changhoon Kim¹¹, Jeong-sun Seo^{11,12}, Koichiro Higasa^{13,14}, Motoki Iwasaki¹⁵, Taiki Yamaji¹⁵, Norie Sawada¹⁵, Shoichiro Tsugane¹⁶, Teruhide Koyama¹⁷, Hiroaki Ikezaki¹⁸, Naoyuki Takashima¹⁹, Keitaro Tanaka²⁰, Kokichi Arisawa²¹, Kiyonori Kuriki²², Mariko Naito²³, Kenji Wakai²⁴, Shinichiro Suna²⁵, Yasuhiko Sakata²⁶, Hiroshi Sato²⁷, Masatsugu Hori²⁸, Yasushi Sakata²⁵, Koichi Matsuda²⁹, Yoshinori Murakami³⁰, Hiroyuki Aburatani¹⁰, Michiaki Kubo³¹, Fumihiko Matsuda¹⁴, Yoichiro Kamatani^{2*}, and Issei Komuro^{6*}

¹Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. ²Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. ³Department of Ocular Pathology and Imaging Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. ⁴Laboratory for Genomics of Diabetes and Metabolism, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. ⁵Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. ⁶Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. ⁷Division for Genomic Medicine, Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan. ⁸Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan. ⁹Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Suita, Japan. ¹⁰Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. ¹¹Bioinformatics Institute, Macrogen Inc., Seoul, Republic of Korea. ¹²Precision Medicine Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. ¹³Department of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, Hirakata, Japan. ¹⁴Human Disease Genomics, Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. ¹⁵Division of Epidemiology, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. ¹⁶Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. ¹⁷Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. ¹⁸Department of Environmental Medicine and Infectious Diseases, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ¹⁹Department of Public Health, Faculty of Medicine, Kindai University, Osaka, Japan. ²⁰Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan. ²¹Department of Preventive Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. ²²Laboratory of Public Health, School of Food and Nutritional Sciences, University of Shizuoka, Shizuoka, Japan. ²³Department of Oral Epidemiology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. ²⁴Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. ²⁵Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan. ²⁶Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. ²⁷School of Human Welfare Studies Health Care Center and Clinic, Kwansei Gakuin University, Nishinomiya, Japan. ²⁸Osaka Prefectural Hospital Organization, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. ²⁹Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Science, Graduate school of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ³⁰Division of Molecular Pathology, Institute of Medial Science, The University of Tokyo, Tokyo, Japan. ³¹RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.

Correspondence should be addressed to K.I, Y.K, and I.K.

1 **Abstract**

2 To elucidate the genetics of coronary artery disease (CAD) in the Japanese population, we conducted a
3 large-scale genome-wide association study (GWAS) of 168,228 Japanese (25,892 cases and 142,336
4 controls) with genotype imputation using a newly developed reference panel of Japanese haplotypes
5 including 1,782 CAD cases and 3,148 controls. We detected 9 novel disease-susceptibility loci and
6 Japanese-specific rare variants contributing to disease severity and increased cardiovascular mortality. We
7 then conducted a transeethnic meta-analysis and discovered 37 additional novel loci. Using the result of the
8 meta-analysis, we derived a polygenic risk score (PRS) for CAD, which outperformed those derived from
9 either Japanese or European GWAS. The PRS prioritized risk factors among various clinical parameters
10 and segregated individuals with increased risk of long-term cardiovascular mortality. Our data improves
11 clinical characterization of CAD genetics and suggests the utility of transeethnic meta-analysis for PRS
12 derivation in non-European populations.

13

1 Coronary artery disease (CAD) is a leading cause of global morbidity and mortality¹. CAD is a common
2 and complex disease, which is also known to be highly heritable². To identify genetic factors underlying
3 CAD, continuous efforts have been undertaken³⁻⁹, which have resulted in the discovery of over 160 CAD
4 susceptibility loci.

5 These achievements have been mainly led by microarray-based genotyping technology in
6 combination with haplotype imputation by publically available reference panels derived from large-scale
7 sequencing projects. Recent advances in high-throughput sequencing technology have now made it
8 possible to reveal the genomes of specific populations, including a substantial number of subjects with
9 relevant diseases. These efforts have successfully discovered population-specific and disease-specific rare
10 haplotypes¹⁰⁻¹² and it is now possible to assess the pathological roles of these variants at the population
11 level.¹³ Another critical achievement in complex-disease genetics is the advancement of the polygenic risk
12 score (PRS). As recently reported, accumulating genetic knowledge and data enables us to derive a PRS
13 which shows clinically relevant performance for case-control discrimination¹⁴⁻¹⁷.

14 Clinical implementation of these technologies is considered promising for the future of precision
15 medicine in CAD. However, these data are mainly derived from large-scale GWAS predominantly
16 conducted with subjects of European descent. Therefore, before these findings can be widely implemented
17 in clinical settings, it is essential to confirm their relevance and robustness in diverse ethnic groups. Such
18 transeethnic analyses could further be used to explore novel findings that are otherwise difficult to discover
19 in a single population¹⁸⁻²⁰.

20 In the present study, to elucidate the genetic architecture of CAD and its transeethnic heterogeneity,
21 we conducted a large-scale GWAS of CAD in the Japanese population (25,892 cases and 142,336
22 controls) in combination with whole-genome sequencing of 4,930 Japanese individuals including rare
23 disease haplotypes. This was followed by a transeethnic meta-analysis (total of 121,234 cases and 527,824
24 controls). Additionally, using the PRS derived from these results and biobank-based phenome-wide
25 analyses, we provide insights into the clinical utility of the PRS which may pave the way to the precision
26 medicine.

1 Results

2 Construction of a CAD reference panel and imputation

3 We sequenced the genomes of 1,782 individuals with early-onset CAD and 3,148 non-CAD controls of
 4 Japanese ancestry from the Biobank Japan (BBJ) project and the Nagahama study (Supplementary Fig. 1a).
 5 After stringent quality control (Methods section), we established 48,305,902 variants [45,505,776 single
 6 nucleotide polymorphisms (SNPs) and 2,800,126 indels]. We found several pathogenic or likely
 7 pathogenic variants of familial hypercholesterolaemia (FH)^{21,22}, which is the most important underlying
 8 genetic condition for CAD (Supplementary Table 1). To leverage the enriched disease-relevant haplotype
 9 information, we constructed a reference panel for haplotype imputation from the whole-genome sequence
 10 data (referred as BBJ_{CAD}). For comparison, we constructed two reference panels from the 1000 Genomes
 11 Project (1KG)²³ dataset under the same pipeline [1KG all subjects (1KG_{ALL}) and 1KG East Asian subjects
 12 (1KG_{EAS})]. To assess the performances of these three different imputation panels, we imputed 179,320
 13 Japanese genotypes with these three reference panels. After filtering by imputation quality ($R^2 \geq 0.3$),
 14 almost double the number of variants remained in the new panel (1KG_{ALL}: 10,284,722; 1KG_{EAS}:
 15 8,482,456; BBJ_{CAD}: 22,136,930, Supplementary Table 2). This difference was based on the improved
 16 imputation quality, especially when considering rare [$1\% \leq$ minor allele frequency (MAF) $< 5\%$] to very
 17 rare (MAF $< 1\%$) variants (Supplementary Fig. 2, 3). We revealed a substantially increased number of
 18 variants with $R^2 \geq 0.3$ in the mechanistically annotated constrained class or curated pathogenic variants
 19 (Supplementary Fig. 4, Supplementary Table 3). For example, the BBJ_{CAD} panel imputed a $6 \times$ higher
 20 number of stop-gain variants and a $5 \times$ higher number of “Pathogenic” variants with $R^2 \geq 0.3$ compared to
 21 the 1KG reference panels.

22 Nine novel loci for CAD detected in Japanese

23 Using the densely imputed genotypes with BBJ_{CAD} reference panel, we performed a GWAS on the case-
 24 control dataset from the BBJ, including 25,892 CAD cases and 142,336 controls (Supplementary Fig.1a),
 25 testing 19,707,525 variants. Although the lambda GC value was inflated at 1.24, the linkage disequilibrium
 26 (LD) score regression intercept²⁴ was 1.06, indicating that 84% of the inflation was likely due to the
 27 polygenic nature of CAD. The liability scale heritability was estimated at 6.5%, which is slightly decreased

1 compared to the results of a recent European study. Forty-eight loci reached genome-wide significance
 2 (Methods section); of them, nine loci were previously unreported (Table 1, Supplementary Table 4,
 3 Supplementary Fig. 5, Supplementary Data Set 1,2). A novel locus on 9q31 harbours *ABCA1*, a critical
 4 gene for high-density lipoprotein cholesterol (HDL) homeostasis, whose disruption causes a severe
 5 deficiency in serum HDL²⁵. The lead variant rs35093463 is located in the intron of *ABCA1*. The higher
 6 frequency of this variant in Japanese (MAF 36%) compared to Europeans (MAF 5%) might have
 7 contributed to the discovery of this loci in this study. Besides, we detected a relatively strong signal [MAF
 8 = 1.0%, odds ratio for CAD development (OR_{CAD}) = 1.61 and its 95% confidence interval (95% CI) = 1.46
 9 – 1.78, $P = 2.3 \times 10^{-21}$] on the chromosome 17q25, where the lead variant rs112735431 causes a
 10 nonsynonymous substitution in the *RNF213* gene. rs112735431 is also known as an established
 11 susceptibility variant for moyamoya disease²⁶, which is a rare cerebrovascular disease with abnormal
 12 vascular formation or obstruction. Since this variant is highly specific to the East Asian population,
 13 previous European studies could not assess its importance in CAD.

14 **Very rare, high-impact signals in the genome-wide significant loci and their pleiotropy**

15 To detect additional CAD-associated signals independent of the lead variants among the genome-wide
 16 significant loci, we performed conditional analysis for each locus of interest. This conditional analysis
 17 revealed 25 additional independent signals (locus-wide $P < 1.0 \times 10^{-5}$) in 48 genome-wide significant loci.
 18 They included rare variants with a high impact on the development of CAD (Fig. 1a, Supplementary Table
 19 5). Of these genome-wide or locus-wide significant variants, we found one stop gain, five missense, and
 20 one in-frame deletion variants. In particular, a stop-gain variants (rs879255211) in the *LDLR* gene showed
 21 a dramatically high OR_{CAD} [MAF = 0.038%, OR_{CAD} (95% CI) = 4.97 (2.49 - 9.93), $P = 5.5 \times 10^{-6}$]. We
 22 also found two missense variants in *PCSK9* [rs151193009, MAF = 0.99%, OR_{CAD} (95% CI) = 0.64 (0.57 –
 23 0.72), $P = 1.21 \times 10^{-14}$; rs564427867, MAF = 1.1%, OR_{CAD} (95% CI) = 1.31 (1.19 – 1.44), $P = 2.7 \times 10^{-8}$],
 24 and one in *APOB* [rs13306206, MAF = 3.8%, OR_{CAD} (95% CI) = 1.38 (1.31 – 1.46), $P = 4.8 \times 10^{-35}$]
 25 surpassing genome- or locus-wide significance thresholds.

26 To explore the biological pathways in which these independent signals play roles in CAD development, we
 27 performed association analyses for 34 clinical indices, including clinical measurements [body mass index

(BMI) and blood pressure], serum laboratory measurements [e.g., total cholesterol (TC), low density lipoprotein cholesterol (LDLC)] and lifestyles (cigarette smoking and alcohol drinking) in the BBJ dataset. We found 121 significant associations ($P < 0.05 / 2,482$) in 29 phenotypes among the 34 tested (Supplementary Fig. 6, Supplementary Table 6). The most frequent association was found between serum TC and these variants. The CAD risk-increasing alleles of these variants are completely matched with the TC increased allele (14/14, Fig. 1b). Especially, rs879255211 showed a large impact on serum TC levels [MAF = 0.038%, $\beta_{TC\text{-raw}}$ (standard error (SE)) = 74.6 (8.90) mg/dL per allele, $P_{TC\text{-adjusted}} = 1.4 \times 10^{-10}$] in accordance with its large impact on CAD development. In addition, rs553577764, a rare intronic variant in *DOCK6* with a high OR_{CAD} , also showed a large impact on serum TC levels [OR_{CAD} (95% CI) = 3.08 (2.22 – 4.26), $P = 1.2 \times 10^{-11}$, $\beta_{TC\text{-raw}}$ (SE) = 57.9 (4.30) mg/dL per allele, $P_{TC\text{-adjusted}} = 1.2 \times 10^{-21}$]. We noted that this variant was in high LD ($R^2 = 0.639$) with rs746959386, which is a missense variant of *LDLR* registered in the ClinVar database as “Likely pathogenic” for FH [MAF = 0.057%, OR_{CAD} (95% CI) = 3.11 (2.21 – 4.37), $P = 4.8 \times 10^{-11}$, $\beta_{TC\text{-raw}}$ (SE) = 63.4 (4.48) mg/dL per allele, $P_{TC\text{-adjusted}} = 8.3 \times 10^{-21}$, Supplementary Table 7]. We also noted that a splicing variant of *LDLR* showed a nominal association with CAD development [rs778408161, MAF = 0.074%, OR_{CAD} (95% CI) = 2.15 (1.44 – 3.21), $P = 1.6 \times 10^{-4}$] and a significant association with TC levels [$\beta_{TC\text{-raw}}$ (SE) = 43.9 (4.85) mg/dL per allele, $P_{TC\text{-adjusted}} = 2.5 \times 10^{-10}$].

The minor allele of rs151193009 in *PCSK9* showed a protective effect against CAD development and a negative effect on serum TC levels [$\beta_{TC\text{-raw}}$ (SE) = -24.3 (1.06) mg/dL per allele, $P_{TC\text{-adjusted}} = 2.3 \times 10^{-111}$]. This variant results in the amino acid substitution, Arg93Cys, which decreases the affinity of *PCSK9* for *LDLR*²⁷, and could have negative impacts on CAD development and TC levels. In contrast, the minor allele for rs564427867 in *PCSK9* showed an increased risk for CAD development and increased TC levels [$\beta_{TC\text{-raw}}$ (SE) = 26.4 (1.06) mg/dL per allele, $P_{TC\text{-adjusted}} = 6.0 \times 10^{-91}$]. rs13306206 is a missense variant of *APOB*, and its minor allele increased the risk of CAD development. In concordance, the risk allele of rs13306206 was associated with an increased level of serum TC [$\beta_{TC\text{-raw}}$ (SE) = 19.9 (0.59) mg/dL per allele, $P_{TC\text{-adjusted}} = 8.6 \times 10^{-155}$]. rs112735431, a missense variant of *RNF213* that was described above, showed a significant association with systolic blood pressure (SBP) [$\beta_{SBP\text{-raw}}$ (SE) = 2.48 (0.66) mmHg per allele, $P_{SBP\text{-adjusted}} = 2.2 \times 10^{-22}$]. Supplementary Table 8 lists the genome-wide or locus-wide associated

coding variants including all of the abovementioned variants. We found that these variants were highly specific to the East Asian population and not found in the European population. Notably, rs879255211 and rs746959386 are not found even in the East Asian population in the 1000 Genomes Project²³ or gnomAD dataset²⁸.

Individuals with rare coding variants in monogenic genes for FH showed the worse cardiovascular outcome

Epidemiological studies have shown that patients with FH have premature myocardial infarctions and worse outcomes because of recurrent ischemia²⁹. However, the definition of FH in previous epidemiological studies was mainly based on clinical criteria. To confirm the association between clinical outcomes and deleterious variants in established FH genes, we assessed the association of the carrier status of the variants detected in the current study (rs564427867 in *PCSK9*, MAF = 1.1%; rs13306206 in *APOB*, MAF = 3.8%, and rs879255211, rs746959386, and rs778408161 in *LDLR*, MAF = 0.038%, 0.057%, and 0.074%, respectively) with clinical indicators. We found that these variants are significantly enriched in the patients with acute coronary syndrome [ACS, defined as a composite of acute myocardial infarction (AMI) and unstable angina] compared to those with stable angina pectoris (SAP) [OR_{ACS/SAP} (95% CI) = 1.23 (1.14 – 1.33) per allele. $P = 1.2 \times 10^{-7}$, Fig. 2a, Supplementary Fig. 7a]; ACS tends to be associated with a more aggressive clinical course than SAP. In addition, individuals with these variants developed AMI at a younger age than non-carriers [effect size on onset age per allele (95% CI) = -1.52 (-2.06; -0.98), $P = 4.7 \times 10^{-8}$, Fig. 2b]. In concordance with these results, as illustrated in Fig. 2c, carriers of these variants showed significantly increased cardiovascular mortality than non-carriers [adjusted hazard ratio (HR) = 1.16, 95% CI = 1.07 – 1.27, $P = 3.5 \times 10^{-4}$, Supplementary Fig. 7b).

Transethnic meta-analysis identified 37 novel CAD-associated loci

To increase the power for detecting further associations with CAD, we conducted a transethnic meta-analysis combining the current Japanese GWAS data and previously published data from two large-scale CAD GWAS, CardiogramPlusC4D (C4D) and UK Biobank (UKBB), mainly involving subjects of European descent (Supplementary Fig. 1b)^{7,9}. To account for the ancestral heterogeneity in each study, we applied the MANTRA algorithm in the analysis³⁰. By combining all three datasets, there was a total of

1 121,234 CAD cases (BBJ: 25,892, C4D: 60,801, UKBB: 34,541) and 527,824 controls (BBJ: 142,336,
2 C4D: 123,504, UKBB: 261,984). A total of 4,804,024 SNPs was tested and 176 loci reached the genome-
3 wide significance threshold [$\log_{10}$ Bayes factor (BF) > 6, Fig. 3, Supplementary Table 9, Supplementary
4 Data Set 3,4]³¹. Forty-three of these loci were not previously reported (Table 2), including six loci that we
5 detected in the current Japanese GWAS. In total, we found 46 previously unreported loci in the Japanese
6 GWAS and the transethnic meta-analysis. Among these loci, we found a novel association on chromosome
7 5q13, which harbours *HMGCR* encoding the late limiting enzyme in endogenous cholesterol synthesis, 3-
8 hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This is the target enzyme of statins, the
9 most prevalent lipid lowering agents. The lead variant rs13354746 is located in 13kb upstream of *HMGCR*,
10 and the risk allele of this variant is highly associated with increased serum TC levels in the Japanese
11 population³².

12 **Transethnic fine mapping of CAD-associated loci**

13 For the fine mapping of the CAD-associated loci, we constructed credible sets for the genome-wide
14 significant loci detected in the transethnic meta-analysis. To assess the contribution of the transethnic
15 meta-analysis to the sizes of the credible sets, we compared the numbers of variants included in the 99%
16 credible sets derived from the transethnic meta-analysis (BBJ, C4D, and UKBB) and the meta-analysis of
17 the two previous European studies (C4D and UKBB, Supplementary Table 10). The sizes of the 99%
18 credible sets in the previously established loci derived from the transethnic meta-analysis were
19 significantly decreased compared to those from the European only analysis [Median number of variants
20 (1st–3rd quantile value) = 13.5 (5 – 33.5) and 19 (6 – 55.5), respectively, $P = 8.7 \times 10^{-9}$, paired Wilcoxon
21 rank-sum test, Supplementary Fig. 8]. We found 28 and 55 lead variants with a posterior probability of
22 association (PPA) greater than 80% and 50%, respectively (Supplementary Table 11), including four
23 coding variants (rs11556924 in *ZC3H1*, rs11601507 in *TRIM5*, rs3741380 in *EHBP1L1*, and rs1169288
24 in *HNF1A*). A previous study implicated three of these variants (rs11556924, rs11601507, and rs3741380)
25 as a causal variant for each locus⁹. rs1169288, a non-synonymous variant in *HNF1A* (Ile27Leu), which
26 encodes a crucial transcription factor highly expressed in the liver and intestine³³, was also previously
27 implicated in cholesterol homeostasis and glucose tolerance^{32,34}, and was predicted to be highly protein
28 damaging (CADD PHREAD score of 23.4)³⁵.

1 Shared allelic effects in the transethnic meta-analysis, and derivation of the transethnic PRS

2 To assess the heterogeneity of allelic effects on CAD development among the studies, we next compared
3 the alternate allele frequency (AAF) and β_{CAD} between the Japanese and two European studies
4 (Supplementary Fig. 9). We observed considerably different allele frequencies between the Japanese and
5 European studies for the 176 lead variants detected in the transethnic meta-analysis. Nevertheless, we
6 found a significant positive correlation and concordant allelic effects of these variants (Spearman's $\rho_{\text{BBJ-}}$
7 $\text{C4D} = 0.81$, $P_{\text{BBJ-C4D}} = 6.2 \times 10^{-42}$; $\rho_{\text{BBJ-UKBB}} = 0.79$, $P_{\text{BBJ-UKBB}} = 8.0 \times 10^{-39}$. directional consistencies were
8 95.5% for BBJ vs. C4D and 94.9% for BBJ vs. UKBB).

9 For further exploration of allelic effect consistency, we compared the allelic effect directions of
10 the variants with various significances (Supplementary Fig. 10). We observed strong correlations of allelic
11 effect direction in the variants with genome-wide significance (concordant rate of allelic effect was 95.9%
12 for variants with $P_{\text{fixed-effect}} < 5 \times 10^{-8}$, 100% for $P_{\text{random-effect}} < 5 \times 10^{-8}$) as mentioned above. Moreover, we
13 found significant concordance of allelic effect direction in variants even with nominal significance (82.0%
14 for $P_{\text{fixed-effect}} < 0.05$, 93.7% for $P_{\text{random-effect}} < 0.05$). In addition, we noted that the random-effect model
15 consistently gives better estimates for variants with shared allelic effect across these P-value thresholds.

16 The transethnic meta-analysis substantially increased the number of significant associations and
17 suggested a shared allelic effect among ethnicities. These results indicate that transethnic meta-analysis
18 could improve the performance of a PRS. To determine the best PRS under such circumstances, we
19 derived the PRS exhaustively from all combinations of summary statistics, reference LD structure, and
20 parameters for derivation. As a result, the random-effects transethnic meta-analysis showed the best
21 performance [Nagelkerke's $R^2 = 0.0776$, the area under the receiver-operator curve (AUC) = 0.664, OR =
22 8.30, Supplementary Fig. 11, Supplementary Table 12], in the independent Japanese case-control
23 validation cohort (1,827 cases, 9,172 controls). This transethnic CAD-PRS outperformed the previously
24 derived CAD-PRS from a European study¹⁶ (Nagelkerke's $R^2 = 0.0479$, AUC = 0.628, OR = 3.70, $P = 1.3$
25 $\times 10^{-6}$ vs. transethnic CAD-PRS) or the PRS derived from the current Japanese GWAS (Nagelkerke's $R^2 =$
26 0.0498, AUC = 0.634, OR = 4.24, $P = 7.1 \times 10^{-7}$, vs. transethnic CAD-PRS).

27 Associations of CAD-PRS with clinical risk factors

To determine the clinical pathways explaining the involvement of the CAD-PRS in CAD pathophysiology, we assessed the correlation between the CAD-PRS and various phenotypes as denoted above. Among the 34 variables tested, significant correlations were observed between 13 clinical factors and CAD-PRS after multiple-testing correction (Fig. 4a, Supplementary Fig. 12, Supplementary Fig. 13, Supplementary Table 13). Most of the traditional CAD risk factors, including blood pressure and lipid or diabetic measurements, showed significant correlations with the CAD-PRS. SBP showed the most significant positive correlation [Spearman's ρ (95% CI) = 0.052 (0.042 – 0.061), $P = 1.9 \times 10^{-24}$], and HDLC showed the third most significant, negative correlation as expected from its clinical consequence [ρ (95% CI) = -0.045 (-0.057; -0.033), $P = 2.9 \times 10^{-13}$]. The CAD-PRS was also significantly correlated with inflammatory markers [white blood cell count (WBC), ρ (95% CI) = 0.018 (0.008 – 0.027), $P = 3.2 \times 10^{-4}$], alcohol drinking [β (95% CI) = -0.048 (-0.069; -0.027), $P = 6.8 \times 10^{-6}$], and cigarette smoking [β (95% CI) = 0.040 (0.016 – 0.065), $P = 1.3 \times 10^{-3}$].

CAD-PRS and cardiovascular mortality

Considering the strong correlation between the CAD-PRS and CAD risk factors (e.g., blood pressure, serum lipid profiles), we hypothesized that CAD-PRS reflects the severity of the genetic background for CAD development, and as a result, the individuals who have a high CAD-PRS will have a poor prognosis. To test this hypothesis, we assessed the impact of the CAD-PRS on mortality in long-term follow-up data. As illustrated in Fig. 4b, individuals with high CAD-PRS showed significantly increased mortality from diseases classified as circulatory system-related [International Statistical Classification of Diseases (ICD)10-I, HR for increasing the CAD-PRS by 1 standard deviation (95% CI) = 1.14 (1.09 – 1.20), $P = 4.4 \times 10^{-7}$, Supplementary Fig. 14, Supplementary Table 14]. Of note, this association was highly specific to circulatory diseases, and other causes of death were not associated with the CAD-PRS. We found significant association between CAD-PRS and all-cause mortality [HR (95% CI) = 1.05 (1.02 – 1.07), $P = 3.4 \times 10^{-4}$], but, when we excluded ICD10-I disease from all-cause mortality, the significance was diminished [HR (95% CI) = 1.02 (0.99 – 1.05), $P = 0.183$]. Furthermore, we divided individuals who died from ICD10-I into three sub-categories: ischemic heart disease (ICD-10 I21-I25), congestive heart failure (ICD-10 I50), and stroke (ICD-10 I60-I69). Two of them showed significant associations with CAD-PRS (i.e., HR (95% CI) = 1.20 (1.07 – 1.34), $P = 1.6 \times 10^{-3}$ for ischemic heart disease, HR (95% CI) = 1.22

1 (1.08 – 1.37), $P = 1.8 \times 10^{-3}$ for congestive heart failure, HR (95% CI) = 1.06 (0.96 – 1.16), $P = 0.25$ for
2 stroke, Fig. 4c, Supplementary Table 14).

3 **Genetic basis of CAD-PRS-associated traits**

4 Finally, to assess the related loci of these CAD-PRS associated traits, we performed association analyses
5 for the 176 lead variants detected in the transethnic meta-analysis and the 13 CAD-PRS-associated traits in
6 the BBJ dataset. Ninety-seven variant-phenotype pairs showed Bonferroni-corrected significance ($P <$
7 $0.05/2,288$, Supplementary Fig. 15, Supplementary Table 15). Serum TC level was the most frequently
8 associated trait (18 associations) and the directions of allelic effect (CAD-risk and TC-increasing) were
9 completely concordant (18/18). To further characterize the relationships between the CAD-associated loci
10 and pleiotropic effects on CAD risk factors, we performed unsupervised clustering for the Z-value matrix
11 of these variants, revealing distinct functional clusters (Supplementary Fig. 16). The loci with positive
12 impacts on serum TC or LDLC levels segregated in Cluster 1. This cluster contains well-characterized loci
13 associated with serum lipid profiles, exemplified by *PCSK9*, *APOB*, *HMGCR*, and *LDLR*. Cluster 2
14 harbours the loci associated with glycaemic traits. The loci in Cluster 3 positively impact on WBCs; the
15 9p21 (*CDKN2B-AS1*) locus is included in this cluster. The loci in cluster 4 positively impact serum
16 triglyceride levels and negatively impact HDLC levels; this cluster also contains *APOA5* and *LPL* loci,
17 which are crucial genes for lipoprotein metabolism. Cluster 5 includes lead variants that affect BMI.
18 Cluster 6, the second largest cluster, contains loci associated with blood pressure.

19 **Discussion**

20 We performed a large-scale CAD GWAS in the Japanese population in combination with whole-genome
21 sequencing, transethnic meta-analysis, and analyses of various types of biobank-based datasets, including
22 clinical phenotypes and long-term follow-up data. In addition to discovering 46 novel loci, we confirmed
23 the clinical relevance of the CAD-PRS to survival prediction and its association with various CAD-
24 associated phenotypes.

25 The use of a population- and disease-specific reference haplotypes improved the imputation
26 quality and enabled assessments of very rare variants with a high impact^{36–38}. In the current study, we

1 found significant associations between a loss-of-function variant in *LDLR* and a high OR for CAD. This
 2 variant was not even found in the large-scale sequencing database (gnomAD) that included a substantial
 3 number of individuals of East Asian ancestry. In addition, such disease-relevant rare variants identified in
 4 this study are highly population specific (Supplementary table 8). These findings warrant further effort for
 5 sequencing of diseased individuals in diverse populations to explore disease mechanisms and molecular
 6 targets. Although the contribution of these rare and very rare variants to the total disease heritability is
 7 small, accurate information on the effects of these variants is essential to provide better medical advice or
 8 genetic counselling for the carriers. Therefore, continuous efforts should be devoted to research on the
 9 behaviour and the impact of such rare variants in the population.

10 In addition to these population-specific rare variants, we found 176 genome-wide associated loci
 11 for CAD including 43 novel loci in the transethnic meta-analysis. The allelic effects of these lead variants
 12 showed almost the same directionality between our Japanese GWAS and previously reported European
 13 GWAS. This result coincides with previous findings that allelic effects of complex diseases or traits are
 14 shared between individuals of East Asian and European descent^{19,20}. Moreover, we observed that a large
 15 proportion of variants with nominal significance showed directional consistency. This shared allelic effect
 16 enabled us to derive a CAD-PRS from a transethnic meta-analysis for Japanese, which outperformed those
 17 derived from either Japanese or European GWAS results. Recently, it was reported that a PRS derived
 18 from a specific ethnic group could not achieve the same performance with other ethnic groups³⁹. Before
 19 the implementation of PRS in clinical practice or public health policies, it is essential to develop PRS that
 20 are impartial and applicable to diverse populations. Therefore, it is crucial to develop a reliable method to
 21 share GWAS results between different ethnic groups effectively. Our results indicate that a transethnic
 22 meta-analysis could assist in the extrapolation of existing data that was obtained with a different ancestry.

23 In the phenome-wide analysis, we found significant dose-dependent relationships between the
 24 CAD-PRS and 13 CAD-relevant traits. This result suggests that the CAD-PRS not only distinguishes case-
 25 control status as a binary trait but also reflects the severity of the genetic background of CAD. Supporting
 26 this hypothesis, survival analysis revealed tight relationships between the CAD-PRS and mortality in long-
 27 term follow-up data. These observations support the feasibility of polygenic risk stratification in non-

1 European populations, especially utilizing the data from European populations, and this warrants further
2 follow-up study.

3 In conclusion, our large-scale genetic analysis allowed us to revise the genetic architecture of
4 CAD and revealed 46 previously unreported loci associated with CAD susceptibility. The transethnic
5 analysis also significantly improved the performance of the CAD-PRS compared to that of population-
6 specific ones. Moreover, biobank-based phenome-wide analysis and survival analysis revealed the
7 behaviour of CAD-PRS in clinical settings through the correlation with clinical risk factors and survival
8 implications. These data provide a fundamental resource for future research, and the clinical
9 implementation of CAD genetics for precision medicine.

10 **URLs.** BioBank Japan, <https://biobankjp.org>; Nagahama cohort, <http://zeroji-cohort.com>; JPHC,
11 <https://epi.ncc.go.jp>; J-MICC, <http://www.jmicc.com>; CARDIoGRAMplusC4D,
12 <http://www.cardiogramplusc4d.org>; Cardiovascular Disease Knowledge portal; <http://www.broadcvdi.org>;
13 UK Biobank, <http://www.ukbiobank.ac.uk>; HapMap project, <http://hapmap.ncbi.nlm.nih.gov>; 1000
14 Genomes Project, <http://www.1000genomes.org>; gnomAD, <https://gnomad.broadinstitute.org>; ClinVar,
15 <https://www.ncbi.nlm.nih.gov/clinvar>; LDSC, <https://github.com/ulik/ldsc/>; Eagle,
16 <https://data.broadinstitute.org/alkesgroup/Eagle>; Minimac3, <https://genome.sph.umich.edu/wiki/Minimac3>;
17 PLINK, <https://www.cog-genomics.org/plink/1.9>; METASOFT, <http://genetics.cs.ucla.edu/meta>;
18 ANNOVAR, <http://annovar.openbioinformatics.org>; LocusZoom, <http://locuszoom.sph.umich.edu>; NBDC
19 Human Database, <https://humandbs.biosciencedbc.jp>.

1 **Online Methods**

2 **Subjects.** Biobank Japan (BBJ)^{40,41} is a hospital-based Japanese national biobank project including data of
 3 approximately 200,000 patients enrolled between 2003 and 2007. Participants were recruited at 12 medical
 4 institutes throughout Japan (Osaka Medical Center for Cancer and Cardiovascular Diseases, the Cancer
 5 Institute Hospital of Japanese Foundation for Cancer Research, Juntendo University, Tokyo Metropolitan
 6 Geriatric Hospital, Nippon Medical School, Nihon University School of Medicine, Iwate Medical
 7 University, Tokushukai Hospitals, Shiga University of Medical Science, Fukujuji Hospital, National
 8 Hospital Organization Osaka National Hospital, and Iizuka Hospital). The Nagahama study is a
 9 community-based cohort study, conducted in Shiga, Japan. Participants were recruited from the general
 10 population aged 30 – 74 years in Nagahama city from 2008 to 2010. The Japan Public Health Center-based
 11 Prospective Study (JPHC)⁴² is an ongoing community-based prospective study conducted in 11 public
 12 health center areas nationwide since 1990. The JPHC enrolled residents aged 40 – 69 years. Japan Multi-
 13 Institutional Collaborative Cohort (J-MICC) Study, community dwellers aged 35 – 69 years were recruited
 14 between 2005 and 2013 in 13 study areas throughout Japan. The Osaka Acute Coronary Insufficiency
 15 Study (OACIS) is a hospital-based registry in which patients with acute myocardial infarction were
 16 enrolled at Osaka University and 24 collaborating hospitals in the Osaka-Hyogo area from 1998 to 2014.
 17 In the Informed consent was obtained from all participants in each study. Our study was approved by the
 18 relevant ethical committees at each facility.

19 **Whole-genome sequencing, quality control, and construction of reference panels.** We sequenced
 20 1,782 samples from patients with early-onset CAD (cases) and 3,148 controls. Whole-genome sequencing
 21 was performed on the HiSeqX5 platform aiming at a 15 × depth, using 2 × 150-bp paired-end reads. All
 22 case samples were obtained from the BBJ cohort (n = 1,782), and control samples were obtained from the
 23 BBJ (n = 1,007) or Nagahama (n = 2,141) cohort. Sequenced data were processed using Picard and aligned
 24 to the hs37d5 reference genome in the BBJ cohort and to hg19 in the Nagahama cohort using the Burrows-
 25 Wheeler algorithm. Genotypes of the samples were called individually in each centre using the
 26 HaplotypeCaller according to Genome Analysis Toolkit best practice for germline SNPs and indels. Per-
 27 sample GVCF genotype data were merged and jointly called using GenotypeGVCFs. We defined
 28 exclusion filters for genotypes as follows: (1) filtered depth (DP) < 5 and (2) quality of the assigned

1 genotype (GQ) < 20. We set these genotypes as missing and excluded variants with call rates < 90% before
2 variant quality score recalibration (VQSR). After VQSR filtering, sample quality control was performed
3 by excluding samples with excess heterozygosity, excess singletons, and closely related samples estimated
4 based on identity by states (PIHAT > 0.2). Principal component analysis restricted samples in the Japanese
5 mainland cluster. After excluding these samples, 1,781 CAD cases and 2,636 controls remained. Then
6 variant quality control was performed excluding variants (1) with more than 5% missing data, (2) with a
7 Hardy Weinberg equilibrium P-value < 1×10^{-6} , (3) with an allele frequency difference in control samples
8 between data processing centres (BBJ and Nagahama cohort, Fisher's exact test $P < 1 \times 10^{-6}$), (4) in the
9 low complexity region, and (5) overlapping with insertions or deletions. After these procedures, we
10 performed case control association analysis using genotypes in whole genome sequence data, and
11 confirmed that the variant quality was well controlled (Supplementary Fig. 17). To construct the reference
12 panel, we excluded singletons from the quality-controlled whole-genome sequencing data, and then
13 haplotype phasing was performed using Eagle (v2.4.1)⁴³. Phased VCFs were transformed into m3vcf
14 format using minimac3 (v2.0.1)⁴⁴. For comparison purposes, we obtained genotypes from the 1000
15 Genomes Project phase 3 (version 5). We then constructed the reference panel under the same pipeline for
16 all subjects (n = 2,504) and for East Asian subjects (n = 504) separately.

17 **Haplotype phasing and imputation of case-control samples.** The subjects included in the GWAS were
18 genotyped using the HumanOmniExpressExome platform (Illumina) or in combination with
19 HumanOmniExpress and HumanExomeBeadChip (Illumina). For variant quality control, we excluded
20 variants with (1) call rates < 99%, (2) Hardy Weinberg Equilibrium P-values < 1.0×10^{-6} , and (3)
21 heterozygous counts less than five. After exclusion of these variants, we performed pre-phasing using
22 Eagle. Phased haplotypes were imputed to the reference panels by minimac3⁴⁴. For evaluation of the
23 imputation quality, we created a phased genotype dataset comprised only of the OmniExpress13 array,
24 imputed up to the 1KG_{EAS}, 1KG_{ALL}, and BBJ_{CAD} panels. After imputation, we compared the imputed
25 dosage and genotypes directly determined by the exome array. Correlations were assessed by Pearson's
26 correlation coefficients. For all downstream analyses, we excluded variants with $R^2 < 0.3$. Genotyped or
27 imputed variants were annotated by ANNOVAR (Build 2017 Jul 7⁴⁵), or the ClinVar database downloaded
28 4 February 2019.

1 **Phenotype.** CAD was defined as a composite of stable angina, unstable angina, and myocardial infarction,
 2 which were determined by a physician upon study inclusion. The demographic features of the case-control
 3 cohort are provided in Supplementary Table 16. The quantitative trait data were obtained from medical
 4 records. Quantitative traits were normalized and adjusted as described below. Before normalization, we
 5 excluded samples from patients younger than 18 years and using the phenotype-specific criteria provided
 6 in Supplementary Table 17. We then corrected the effect of medication as follows. For individuals taking
 7 cholesterol-lowering drugs, TC and LDLC levels were corrected by dividing by 0.7 as previously
 8 reported^{46,47}. For individuals taking antihypertensive drugs, 15 mmHg was added to the SBP and 10
 9 mmHg to the diastolic blood pressure readings⁴⁸. We next constructed a linear model for these phenotypes
 10 with sex, age, age², the top 10 principal components and disease status. For WBC and C-reactive protein
 11 (CRP), smoking status was also introduced to the model. Using these models, we computed the residuals
 12 of the phenotype for each individual. The residuals were normalized by inverse-rank normalization and
 13 used as continuous variables⁴⁹. Samples with excess heterozygosity, excess missing genotypes, a non-
 14 Japanese outlier identified by principal component analysis, and closely related samples estimated based
 15 on identity by states (PIHAT > 0.2) were excluded from the case-control or quantitative phenotype
 16 association studies.

17 **GWAS.** The case-control association analysis was performed by logistic regression, implemented in
 18 PLINK2⁵⁰. Sex, age, age², and the top 10 principal components were included in the model as covariates.
 19 We tested 19,707,525 variants with a minor allele frequency (MAF) $\geq 0.02\%$ in case-control population,
 20 because our reference panel contained almost ten thousand haplotypes and variants with minor allele
 21 counts ≥ 2 (0.02%). The genome-wide significance threshold was set at $P < 5 \times 10^{-8}$ for variants with MAF
 22 $\geq 1\%$, and $P < 3.93 \times 10^{-9}$ (0.05/12,710,563) for those with MAF < 1% (number of variants with MAF <
 23 1% = 12,710,563). To define a locus, we created a set of genomic ranges adding 500 kb bilaterally for all
 24 variants with genome-wide significance, and then merged overlapping ranges. In the MHC region
 25 (chromosome 6: 25,000,000–35,000,000 bp), we added 1 Mb to the signal bilaterally. Previously reported
 26 loci were also created in the same manner based on the curated top variants. Significant loci without
 27 overlap and a lead variant not in LD (<0.10) in both the East Asian or European population with
 28 previously reported loci were considered novel. LD was estimated using genotypes of the 1KG dataset. For

1 quantitative traits, we performed linear regression analysis implemented in PLINK2 for normalized
2 phenotypes as described above.

3 **LD score regression and heritability estimation.** We performed LD score regression with ldsc software
4 to estimate bias from population stratification and explained heritability²⁴. We used the 1KG EAS
5 population as the reference LD panel and included only variants present in HapMap3 SNPs. For the
6 calculation of liability scale heritability, we assumed that the CAD prevalence in the Japanese population
7 is 0.8% based on a Japanese government report published in 2009 (<https://www.mhlw.go.jp/>).

8 **Stepwise conditional analysis.** To identify statistically independent signals in the loci, we performed
9 sample-level stepwise conditional analysis for each genome-wide significant locus defined as denoted
10 above. In the first step, we added the dosage of the lead variant to the covariates and performed logistic
11 regression for all variants in the locus. If we found a locus-wide significant association ($P < 1 \times 10^{-5}$), we
12 additionally introduced the dosage of the most significant variant to the covariates. This procedure was
13 repeated until none of the variants showed locus-wide significance.

14 **Meta-analysis.** We obtained summary statistics for the European CAD-GWAS from the website of the
15 CARDIoGRAM plus C4D consortiums (<http://www.cardiogramplusc4d.org/data-downloads/>)⁷ and online
16 supplementation of a previous report (<https://data.mendeley.com/datasets/2zdd47c94h/1>)⁹. We aligned the
17 β and allele frequency to the alternate allele of hg19 and then merged only SNPs with an MAF $\geq 1\%$ in all
18 the summary statistics. The transethnic meta-analysis was performed using MANTRA(v2)³⁰ and genome-
19 wide significance was set at $\log_{10} \text{BF} > 6$ according to a previous simulation result³¹. We excluded $\log_{10}$
20 BF for heterogeneity > 6 . For PRS derivation, β and P-values were calculated by fixed- and random-effects
21 meta-analyses using METASOFT (v2)⁵¹.

22 **Estimation of allelic concordance.** To obtain LD-independent variant sets at various significance levels,
23 we performed *P*-value thresholding for each *P*-value threshold from the summary statistics obtained from
24 the fixed-effect transethnic meta-analysis and random-effect transethnic meta-analyses. For these variant
25 sets, we calculated the Pearson's correlation coefficient of the β between the European study and Japanese
26 studies. The 1KG European population was used as the LD reference and the LD threshold was fixed at 0.8.

1 **Credible set analysis.** To construct sets of variants that likely include causal variants in each significant
2 locus identified by the transethnic meta-analysis, we performed a credible set analysis. For each genome-
3 wide associated locus, we calculated the PPA (π)⁵² for all variants as follows:

$$4 \quad \pi_j = \frac{\lambda_j}{\sum_k \lambda_k}$$

5 Here, λ denotes the BF for variant j , and k denotes all of the variants included in the locus. We listed the
6 variants in order of decreasing PPA, and then constructed the 99% credible set including variants from the
7 top PPA until the cumulative PPA reached 0.99. For comparison, we performed the European meta-
8 analysis using the C4D and the UKBB datasets (referred to as the European analysis).

9 **PRS.** We derived the PRS by the P -value thresholding (P/T) method using summary statistics from the 1)
10 the Japanese GWAS with MAF > 0.01, 2) the transethnic meta-analysis of the fixed-effect model, and 3)
11 the mixed-effect model. We used the P -value thresholds 1.0, 0.5, 0.1, 0.05, 0.01, 1×10^{-3} , 5×10^{-4} , 5×10^{-6} ,
12 5×10^{-8} , and R^2 thresholds 0.2, 0.4, 0.6, and 0.8. Pruning and thresholding procedure was performed by
13 PLINK software version 1.90b3.37. Individual risk scores were computed with derived weights in
14 independent case-control cohorts (case = 1,827, control = 9,172) by multiplying the genotype dosage and
15 corresponding weight using PLINK2 software. To assess the performance of the PRS, we calculated the
16 Nagelkerke's R^2 , the AUC values and OR using a logistic regression model adjusted by age and sex. OR
17 indicates the ratio of disease prevalence in the top decile to that in the bottom decile. For a comparison of
18 AUC values, we performed DeLong's test implemented in the pROC package for R. The previously
19 derived PRS from the European study¹⁶ was downloaded from Cardiovascular Disease Knowledge Portal
20 (<http://www.broadcvdi.org>).

21 **Survival analysis.** For survival analysis, we obtained survival follow-up data with the cause of death
22 under the ICD-10 code for 132,737 individuals from the BBJ project. Data collection and feasibility were
23 reported previously^{40,41}. Briefly, survival status was collected from medical records or resident card. Then
24 we obtained vital statistics from the Statistics and Information Department of Ministry of Health, Labor
25 and Welfare in Japan, and identified the cause of death according to ICD-10. The follow-up rate was 97%
26 and the median follow-up period was 7.7 years. We divided the cause of death based on ICD-10

1 classifications and excluded categories with fewer than 100 events. HRs and associated P-values were
 2 calculated for genotype dosage or PRS by the proportional hazard model adjusting for sex, age, age², top
 3 10 principal components, and disease status. Analyses were performed with the R package survival, and
 4 survival curves were estimated using the R package survminer with modification.

5 **PRS associated phenotypes.** For clinical evaluation of the CAD-PRS, we randomly split and withheld 1/3
 6 of the control samples. Using the remaining control samples and all case samples, we re-performed the
 7 Japanese GWAS, transethnic meta-analysis, and PRS derivation (Supplementary Fig. 1c). Using the
 8 derived model, we calculated the PRS for the withheld control samples, and assessed relationships between
 9 the CAD-PRS and clinical indices including 32 numerical clinical traits and two binary lifestyle traits (i.e.,
 10 cigarette smoking and alcohol drinking). For the numerical traits, we calculated Spearman's correlation
 11 coefficients, associated confidence intervals, and P-values. For the binomial traits, we performed logistic
 12 regression adjusted by sex, age, age², top ten principal components, and disease status. We set the
 13 significance threshold at $P < 0.05/34$.

14 **Data availability.** Summary statistics of the Japanese GWAS will be publically available in National
 15 Bioscience Database Center (research ID hum0014, <https://humandbs.biosciencedbc.jp/>).

16

1 **Acknowledgments**

2 We appreciate the staff of BBJ for their excellent assistance in collecting samples and clinical information.
3 We also thank the Nagahama study, the Japan Public Health Centre-based prospective Study (JPHC) study
4 and Japan Multi-Institutional Collaborative Cohort (J-MICC) Study, and Osaka Acute Coronary
5 Insufficiency Study (OACIS) study for their invaluable contributions to the study. We are grateful to the
6 CARDIoGRAMplusC4D investigators, P.v.d Harst, and N Verweij for making their data publically
7 available. We thank A.P. Morris for providing us with MANTRA software with valuable advice.

8 **Author Contributions**

9 S.K., K.I., C.T., M.K., and Y.K. conceived and designed the study. C.K., J.S., K.H., and F.M. collected,
10 managed and genotyped the Nagahama cohort. K.M, Y. Murakami, and M.K. collected and managed the
11 BBJ sample. M.I, T.Y, N.S, and S.T collected and managed the JPHC study. T.K., H. Ikezaki, N.T., K.T.,
12 K.A., K.K., M.N., and K.W. collected and managed the J-MICC study. S.S., Yasuhiko Sakata, H.S., M.
13 Hori, Yasushi Sakata collected and managed the OACIS study. C.T., Y. Momozawa, A.T., M.K., and Y.K.,
14 performed genotyping. S.K., K.I., C.T., and Y.K. performed statistical analysis. S.K., K.I., C.T., M.A., M.
15 Horikoshi, H. Matsunaga, H. Ieki., K.O., Y.O. contributed to data processing, analysis and interpretation.
16 S.N., H. Morita, H. Akazawa., H. Aburatani, and I.K. supervised the study. S.K. and K.I. wrote the
17 manuscript and many authors also provided valuable edits.

18 **Competing Financial Interests**

19 The authors declare no conflicts of interest associated with this manuscript.

20 **Source of Funding**

21 This research was funded by the GRIFIN project of Japan Agency for Medical Research and Development
22 (AMED). BBJ was supported by the Tailor-Made Medical Treatment Program of the Ministry of
23 Education, Culture, Sports, Science, and Technology (MEXT) and AMED. The JPHC Study was
24 supported by National Cancer Center Research and Development Fund since 2011 and a grant-in-aid for
25 Cancer Research from the Ministry of Health, Labour and Welfare of Japan from 1989 to 2010. The J-

1 MICC study was supported by Grants-in-Aid for Scientific Research for Priority Areas of Cancer (No.
2 17015018) and Innovative Areas (No. 221S0001) and by JSPS KAKENHI Grant Numbers JP16H06277
3 from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The Nagahama study
4 was supported by JSPS, Grant-in-Aid for Scientific Research (C), KAKENHI Grant Number JP17K07255
5 and JP17KT0125, and the Practical Research Project for Rare/Intractable Diseases from Japan Agency for
6 Medical Research and Development, AMED, under Grant Number JP16ek0109070h0003,
7 JP18kk0205008h0003, JP18kk0205001s0703 JP19ek0109283h0003, and JP19ek0109348h0002.

References

1. Wang, H. *et al.* Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **388**, 1459–1544 (2016).
2. Marenberg, M. E., Risch, N., Berkman, L. F., Floderus, B. & de Faire, U. Genetic Susceptibility to Death from Coronary Heart Disease in a Study of Twins. *N. Engl. J. Med.* **330**, 1041–1046 (1994).
3. Ozaki, K. *et al.* Functional SNPs in the lymphotoxin- α gene that are associated with susceptibility to myocardial infarction. *Nat. Genet.* **32**, 650–654 (2002).
4. Samani, N. J. *et al.* Genomewide Association Analysis of Coronary Artery Disease. *N. Engl. J. Med.* **357**, 443–453 (2007).
5. Willer, C. J. *et al.* Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat. Genet.* **40**, 161–169 (2008).
6. Erdmann, J. *et al.* New susceptibility locus for coronary artery disease on chromosome 3q22.3. *Nat. Genet.* **41**, 280–282 (2009).
7. Nikpay, M. *et al.* A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.* **47**, 1121–1130 (2015).
8. Nelson, C. P. *et al.* Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat. Genet.* **49**, 1385–1391 (2017).
9. van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ. Res.* **122**, 433–443 (2018).
10. Fuchsberger, C. *et al.* The genetic architecture of type 2 diabetes. *Nature* **536**, 41–47 (2016).
11. de Lange, K. M. *et al.* Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. *Nat. Genet.* **49**, 256–261 (2017).
12. Khera, A. V. *et al.* Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. *Circulation* **139**, 1593–1602 (2019).
13. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat. Genet.* **50**, 1505–1513 (2018).
14. Mega, J. L. *et al.* Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. *Lancet* **385**, 2264–2271 (2015).

- 1 15. Khera, A. V. *et al.* Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. *N. Engl. J. Med.*
2 **375**, 2349–2358 (2016).
- 3 16. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with risk
4 equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
- 5 17. Inouye, M. *et al.* Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for
6 Primary Prevention. *J. Am. Coll. Cardiol.* **72**, 1883–1893 (2018).
- 7 18. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium *et al.* Genome-wide trans-
8 ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat.*
9 *Genet.* **46**, 234–244 (2014).
- 10 19. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **506**,
11 376–381 (2014).
- 12 20. Akiyama, M. *et al.* Genome-wide association study identifies 112 new loci for body mass index in the
13 Japanese population. *Nat. Genet.* **49**, 1458–1467 (2017).
- 14 21. Landrum, M. J. *et al.* ClinVar: public archive of relationships among sequence variation and human
15 phenotype. *Nucleic Acids Res.* **42**, D980–D985 (2014).
- 16 22. Maruyama, T. *et al.* Common mutations in the low-density-lipoprotein-receptor gene causing familial
17 hypercholesterolemia in the Japanese population. *Arterioscler. Thromb. Vasc. Biol.* **15**, 1713–1718 (1995).
- 18 23. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68–74
19 (2015).
- 20 24. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-
21 wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 22 25. Bodzioch, M. *et al.* The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease.
23 *Nat. Genet.* **22**, 347–351 (1999).
- 24 26. Kamada, F. *et al.* A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.
25 *J. Hum. Genet.* **56**, 34–40 (2011).
- 26 27. Gustafsen, C. *et al.* Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. *Nat. Commun.* **8**,
27 503 (2017).
- 28 28. Karczewski, K. J. *et al.* Variation across 141,456 human exomes and genomes reveals the spectrum of loss-
29 of-function intolerance across human protein-coding genes. Preprint at
30 <https://www.biorxiv.org/content/10.1101/531210v3> (2019)

- 1 29. Nanchen, D. *et al.* Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes.
2 *Circulation* **134**, 698–709 (2016).
- 3 30. Morris, A. P. Transethnic meta-analysis of genomewide association studies. *Genet. Epidemiol.* **35**, 809–822
4 (2011).
- 5 31. Wang, X. *et al.* Comparing methods for performing trans-ethnic meta-analysis of genome-wide association
6 studies. *Hum. Mol. Genet.* **22**, 2303–2311 (2013).
- 7 32. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell types to
8 complex human diseases. *Nat. Genet.* **50**, 390–400 (2018).
- 9 33. GTEx Consortium. Genetic effects on gene expression across human tissues. *Nature* **550**, 204–213 (2017).
- 10 34. Teslovich, T. M. *et al.* Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* **466**,
11 707–713 (2010).
- 12 35. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness
13 of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–D894 (2019).
- 14 36. UK10K Consortium *et al.* Improved imputation of low-frequency and rare variants using the UK10K
15 haplotype reference panel. *Nat. Commun.* **6**, 8111 (2015).
- 16 37. The Haplotype Reference Consortium *et al.* A reference panel of 64,976 haplotypes for genotype
17 imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
- 18 38. Natarajan, P. *et al.* Deep-coverage whole genome sequences and blood lipids among 16,324 individuals.
19 *Nat. Commun.* **9**, 1–12 (2018).
- 20 39. Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat.*
21 *Genet.* **51**, 584–591 (2019).
- 22 40. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *J. Epidemiol.* **27**, S2–S8
23 (2017).
- 24 41. Hirata, M. *et al.* Cross-sectional analysis of BioBank Japan clinical data: A large cohort of 200,000 patients
25 with 47 common diseases. *J. Epidemiol.* **27**, S9–S21 (2017).
- 26 42. Tsugane, S. & Sawada, N. The JPHC Study: Design and Some Findings on the Typical Japanese Diet. *Jpn.*
27 *J. Clin. Oncol.* **44**, 777–782 (2014).
- 28 43. Loh, P.-R., Palamara, P. F. & Price, A. L. Fast and accurate long-range phasing in a UK Biobank cohort.
29 *Nat. Genet.* **48**, 811–816 (2016).
- 30 44. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).

- 1 45. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-
2 throughput sequencing data. *Nucleic Acids Res.* **38**, e164–e164 (2010).
- 3 46. Benn, M., Watts, G. F., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Mutations causative of familial
4 hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study
5 estimated a prevalence of 1 in 217. *Eur. Heart J.* **37**, 1384–1394 (2016).
- 6 47. Khera, A. V. *et al.* Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia
7 Genes in Patients With Severe Hypercholesterolemia. *J. Am. Coll. Cardiol.* **67**, 2578–2589 (2016).
- 8 48. Yang, J. *et al.* *FTO* genotype is associated with phenotypic variability of body mass index. *Nature* **490**,
9 267–272 (2012).
- 10 49. Newton-Cheh, C. *et al.* Genome-wide association study identifies eight loci associated with blood pressure.
11 *Nat. Genet.* **41**, 666–676 (2009).
- 12 50. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
13 *GigaScience* **4**, 7 (2015).
- 14 51. Han, B. & Eskin, E. Random-Effects Model Aimed at Discovering Associations in Meta-Analysis of
15 Genome-wide Association Studies. *Am. J. Hum. Genet.* **88**, 586–598 (2011).
- 16 52. The Wellcome Trust Case Control Consortium *et al.* Bayesian refinement of association signals for 14 loci
17 in 3 common diseases. *Nat. Genet.* **44**, 1294–1301 (2012).

Table 1 | Novel loci identified by Japanese GWAS

CHR	POS	Locus		REF	ALT	rsID	Gene	Annotation	AAF	OR	95%CI		P
		From	To								Lower	Upper	
2	230,007,146	229,503,354	230,514,441	C	T	rs62190384	<i>PID1</i>	Intronic	0.49	0.95	0.93	0.96	9.6E-09
5	4,094,165	3,523,315	4,594,165	G	T	rs10041378	<i>IRX1,LINC02114</i>	Intergenic	0.24	0.93	0.91	0.96	5.6E-09
6	74,415,868	73,915,867	74,915,868	A	C	rs56171536	<i>CD109</i>	Intronic	0.05	1.13	1.08	1.18	4.2E-08
8	69,431,711	68,931,710	69,931,711	G	A	rs2380472	<i>C8orf34</i>	Intronic	0.13	0.92	0.89	0.95	2.5E-08
9	107,586,238	107,085,015	108,104,394	C	A	rs35093463	<i>ABCA1</i>	Intronic	0.36	1.06	1.04	1.08	3.5E-09
11	203,235	0	738,058	A	G	rs73386640	<i>BET1L</i>	3'UTR	0.13	1.10	1.07	1.13	2.3E-10
12	10,876,573	10,345,946	11,393,295	C	A	rs2607903	<i>YBX3</i>	Upstream	0.61	0.94	0.92	0.96	6.6E-10
17	78,358,945	77,612,997	79,262,582	G	A	rs112735431	<i>RNF213</i>	Nonsynonymous SNV	0.01	1.61	1.46	1.78	2.3E-21
18	20,009,691	19,509,602	20,509,691	T	C	rs9951447	<i>CTAGE1,LOC101927571</i>	Intergenic	0.57	1.06	1.04	1.08	4.7E-09

Summary statistics of novel loci that reached genome-wide significance in the Japanese GWAS (25,892 cases and 142,336 controls). CHR, Chromosome; POS, position(hg19); REF, reference allele; ALT, alternate allele; rsID, reference SNP cluster ID; AAF, alternate allele frequency; OR, odds ratio; CI, confidence interval; UTR, untranslated region.

Table 2 | Novel loci identified by Transethnic meta-analysis

CHR	POS	Locus		REF	ALT	rsID	Gene	Annotation	MANTRA			Fixed effect				
		From	To						Beta	SE	Log ₁₀ BF	Beta	SE	P	Q	P _Q
1	114,448,389	113,926,000	114,950,964	C	T	rs11552449	<i>DCLRE1B</i>	Nonsynonymous SNV	0.037	0.006	8.1	0.037	0.006	3.7E-10	0.2	8.9E-01
1	218,827,855	218,317,531	219,358,746	T	C	rs1481345	<i>MIR548F3</i>	ncRNA Intronic	-0.031	0.005	7.9	-0.031	0.005	4.7E-10	2.0	3.7E-01
2	62,878,928	62,357,974	63,679,076	G	C	rs7420881	<i>TMEM17, EHPBP1</i>	Intergenic	0.032	0.005	7.1	0.032	0.005	3.9E-09	0.5	7.7E-01
2	65,499,468	64,982,115	66,030,347	G	A	rs72822411	<i>ACTR2, SPRED2</i>	Intergenic	0.036	0.006	6.9	0.036	0.006	6.1E-09	3.1	2.2E-01
2	112,656,652	112,155,241	113,263,025	G	A	rs7604403	<i>MERTK</i>	Intronic	0.034	0.006	7.2	0.034	0.006	3.5E-09	1.5	4.7E-01
2	144,158,418	143,651,523	144,698,216	T	C	rs12469628	<i>ARHGAP15</i>	Intronic	-0.040	0.006	9.3	-0.041	0.006	1.9E-11	1.2	5.5E-01
2	163,110,536	162,610,535	163,610,536	A	G	rs2111485	<i>FAP, IFIH1</i>	Intergenic	0.029	0.005	6.2	0.029	0.005	3.7E-08	0.9	6.5E-01
2	230,009,317	229,480,420	230,515,954	C	T	rs7566501	<i>PID1</i>	Intronic	-0.035	0.005	10.5	-0.035	0.005	1.9E-12	7.2	2.7E-02
3	69,820,782	69,302,901	70,409,425	T	C	rs12714757	<i>MITF</i>	Intronic	-0.036	0.006	8.4	-0.036	0.006	1.5E-10	2.2	3.3E-01
4	56,316,979	55,816,978	56,816,979	T	C	rs11133381	<i>CLOCK</i>	Intronic	-0.028	0.005	6.0	-0.027	0.005	4.8E-08	2.1	3.6E-01
4	73,420,634	72,919,494	73,984,862	G	A	rs13105983	<i>ADAMTS3</i>	Intronic	-0.029	0.005	7.3	-0.029	0.005	2.8E-09	3.4	1.8E-01
4	146,809,998	146,259,606	147,321,725	T	G	rs10006310	<i>ZNF827</i>	Intronic	-0.029	0.005	7.2	-0.029	0.005	3.2E-09	1.0	6.0E-01
4	186,692,853	186,190,488	187,193,134	T	C	rs7680806	<i>SORBS2</i>	Intronic	0.037	0.007	6.4	0.037	0.007	3.0E-08	4.9	8.4E-02
5	4,023,730	3,506,098	4,600,989	C	T	rs548581	<i>IRX1, LINC02114</i>	Intergenic	0.022	0.005	9.2	0.022	0.005	1.6E-05	31.0	1.8E-07
5	74,619,132	74,119,131	75,119,132	C	T	rs13354746	<i>ANKRD31, HMGCR</i>	Intergenic	0.031	0.006	6.4	0.032	0.006	2.5E-08	1.5	4.7E-01
6	90,314,917	89,814,916	90,829,895	A	G	rs9351209	<i>ANKRD6</i>	Intronic	-0.029	0.005	6.4	-0.029	0.005	1.8E-08	3.4	1.8E-01
6	149,714,790	149,153,791	150,244,924	G	T	rs2744427	<i>TAB2</i>	Intronic	-0.036	0.007	6.3	-0.036	0.007	2.4E-08	3.0	2.3E-01
7	35,286,471	34,769,624	35,802,478	C	A	rs4723406	<i>TBX20</i>	Intronic	-0.033	0.005	8.8	-0.033	0.005	7.9E-11	0.7	7.0E-01
7	56,122,058	55,622,057	56,622,058	A	T	rs6593297	<i>CCT6A</i>	Intronic	-0.031	0.005	7.0	-0.031	0.005	4.0E-09	0.3	8.5E-01
8	25,064,984	24,561,806	25,564,984	G	A	rs9693598	<i>DOCK5</i>	Intronic	-0.044	0.008	6.6	-0.044	0.008	1.6E-08	0.1	9.4E-01
8	95,260,225	94,750,557	95,781,052	A	G	rs2623168	<i>CDH17, GEM</i>	Intergenic	0.047	0.008	7.8	0.047	0.008	1.1E-09	6.7	3.5E-02
8	102,832,405	102,313,394	103,395,016	C	T	rs13255004	<i>NCALD</i>	Intronic	0.034	0.006	6.7	0.034	0.006	1.1E-08	3.8	1.5E-01
9	107,586,238	107,085,015	108,104,394	C	A	rs35093463	<i>ABCA1</i>	Intronic	0.054	0.007	11.0	0.055	0.008	3.4E-13	2.3	3.2E-01
10	74,682,633	73,808,317	75,191,035	T	G	rs11000448	<i>OIT3</i>	Intronic	-0.053	0.008	8.8	-0.052	0.008	3.9E-11	2.4	3.0E-01
10	102,075,479	101,575,478	102,575,479	G	A	rs603424	<i>PKD2L1</i>	Intronic	0.040	0.007	6.9	0.040	0.007	5.8E-09	0.0	9.9E-01
11	224,845	0	738,058	G	C	rs73392700	<i>SIRT3</i>	Intronic	0.064	0.010	9.2	0.064	0.010	3.3E-11	6.5	4.0E-02
11	32,441,377	31,875,668	32,941,377	C	T	rs7115190	<i>WT1</i>	Intronic	0.032	0.005	7.5	0.032	0.005	1.6E-09	1.0	6.1E-01
11	61,277,698	60,777,697	61,778,918	A	G	rs11230728	<i>LRRC10B</i>	3'UTR	-0.036	0.006	6.3	-0.036	0.006	3.6E-08	1.5	4.8E-01
11	118,950,217	118,428,252	119,450,217	C	G	rs1307145	<i>VPS11</i>	Intronic	0.031	0.005	6.8	0.031	0.005	7.2E-09	2.5	2.8E-01
11	120,198,093	119,698,092	120,847,715	G	A	rs1893261	<i>TMEM136</i>	Synonymous SNV	0.028	0.005	6.3	0.028	0.005	3.1E-08	2.4	3.0E-01
12	10,876,573	10,376,572	11,392,139	C	A	rs2607903	<i>YBX3</i>	Upstream	-0.040	0.007	7.2	-0.040	0.007	4.8E-09	9.3	9.7E-03
13	98,859,335	98,357,228	99,366,535	G	A	rs9556903	<i>FARP1</i>	Intronic	-0.044	0.007	8.8	-0.044	0.007	7.9E-11	6.2	4.5E-02
14	103,900,481	103,349,714	104,484,616	A	G	rs35224956	<i>MARK3</i>	Intronic	0.031	0.005	7.2	0.031	0.005	3.2E-09	0.7	7.2E-01
15	74,223,716	73,721,297	74,782,343	G	C	rs28522673	<i>LOXL1</i>	Intronic	0.044	0.006	9.4	0.044	0.007	1.8E-11	4.5	1.1E-01
15	81,377,717	80,834,756	81,898,791	C	A	rs1879454	<i>TLNDR1, CFAP161</i>	Intergenic	-0.036	0.006	8.1	-0.036	0.006	4.5E-10	3.7	1.6E-01
16	1,584,618	1,084,617	2,084,866	T	C	rs2076438	<i>IFT140, TMEM204</i>	Intronic	0.028	0.005	6.2	0.028	0.005	3.1E-08	0.9	6.4E-01
16	15,917,838	15,412,982	16,417,838	C	G	rs216158	<i>MYH11</i>	Intronic	-0.029	0.005	6.1	-0.029	0.005	3.9E-08	0.1	9.6E-01
16	86,699,163	86,198,030	87,216,058	A	G	rs12444314	<i>FOXL1, LINC02189</i>	Intergenic	0.032	0.006	7.2	0.032	0.005	3.6E-09	0.2	9.1E-01
17	49,308,707	48,808,706	49,808,707	C	T	rs4794213	<i>MBTD1</i>	Intronic	-0.028	0.005	6.1	-0.028	0.005	3.6E-08	0.3	8.7E-01
17	66,469,400	65,953,304	66,970,892	T	G	rs2952286	<i>PRKAR1A</i>	Intronic	0.035	0.006	7.7	0.035	0.006	5.3E-10	3.6	1.6E-01
18	19,998,810	19,498,809	20,584,756	G	C	rs948386	<i>CTAGE1</i>	Upstream	0.036	0.005	10.8	0.036	0.005	8.1E-13	5.3	7.2E-02
20	62,709,274	62,190,682	63,025,520	G	A	rs12625329	<i>RGS19</i>	Intronic	-0.031	0.005	7.4	-0.031	0.005	2.1E-09	2.8	2.5E-01
22	30,669,883	30,167,276	31,169,883	G	A	rs6006426	<i>OSM, CASTOR1</i>	Intergenic	0.030	0.005	8.0	0.031	0.005	4.1E-10	5.7	5.7E-02

Summary statistics of novel loci that reached genome-wide significance in the transethnic meta-analysis (121,234 cases and 527,824 controls). CHR, Chromosome; POS, position(hg19); REF, reference allele; ALT, alternate allele; rsID, reference SNP cluster ID; SE, standard error; BF, Bayes factor; Q, Cochran's Q value; P_Q, P value for Chochran's Q test; SNV, single nucleotide variant; ncRNA, non-coding RNA.

Fig. 1 | Distinct signals in CAD development and serum TC levels. **a**, The odds ratio for CAD development of the 73 independent signals in Japanese GWAS (25,892 cases, 142,336 controls) are plotted against the minor allele frequency. Rare variants ($MAF < 0.05$) are plotted in blue, and others in grey. **b**, Beta values for serum TC levels estimated by the linear regression model ($n = 134,314$) are plotted against beta values for CAD development. Variants showing significant associations for serum TC levels are plotted in orange. CAD, coronary artery disease; TC, total cholesterol, GWAS, genome-wide association study; MAF, minor allele frequency; OR, odds ratio.

Fig. 2 | Impact of the deleterious variant in FH genes in CAD subtypes, age of onset of AMI, and long-term cardiovascular mortality. **a**, Each point indicates the odds ratio for developing ACS with the error bar indicating its 95% confidence intervals for alternate allele dosage of deleterious variants for each gene. Individuals with SAP were used as controls. **b**, Each point indicates effect sizes for the onset age of AMI of alternate allele dosage with the error bar indicating the 95% confidence interval. **c**, Adjusted curves for mortality from diseases of the circulatory system (ICD10.I) stratified by carrier status of deleterious variants in established FH genes (rs564427867 in *PCSK9*; rs13306206 in *APOB*; rs879255211, rs746959386, and rs778408161 in *LDLR*) are shown. ACS, acute coronary syndrome; SAP, stable angina pectoris; AMI, acute myocardial infarction; FH, familial hypercholesterolaemia.

Fig. 3 | Manhattan plots for transethnic meta-analysis. The results of the case-control association study in the transethnic meta-analysis (CAD case 121,234, control 527,824) are shown. The $\log_{10}\text{BF}$ on the y-axes are plotted against the genomic position (hg19) on the x-axes. Variants in 43 novel and 133 previously reported loci are presented in orange and blue, respectively. Dashed lines indicate genome wide significant thresholds ($\text{Log}_{10}\text{BF} = 6$). BF, Bayes Factor.

Fig. 4 | Correlation between transethnic CAD-PRS and clinical indices. **a**, Upper panel; Each point indicates Spearman's correlation coefficient between CAD-PRS and clinical indices. Error bars indicates 95% confidence intervals. Lower panel; Each point indicates a beta coefficient for 1SD increase in CAD-PRS estimated by the logistic regression model. Significant correlations or associations are shown in orange ($P < 0.05/34$). **b**, Adjusted curves for mortality from ICD10.I diseases estimated by Cox's proportional hazard model are shown. Individuals are stratified into high PRS (top 20 percentile, orange), low PRS (bottom 20 percentile, blue), and intermediate PRS (others, black). **c**, Each point indicates a hazard ratio of 1SD increase in CAD-PRS for mortality from ICD10.I subtypes. Error bars represents the 95% confidence interval. PRS, polygenic risk score; ICD10, International Statistical Classification of Diseases and Related Health Problems 10th Revision; IHD, ischemic heart disease; CHF, congestive heart failure; SD, standard deviation. Abbreviations of other phenotypes are defined in Supplementary Table 17.